Search

Your search keyword '"Saotome, Takashi"' showing total 31 results
Start Over Author "Saotome, Takashi"
31 results on '"Saotome, Takashi"'

1. Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma

Author

Niwa, Kazutomo, Kawakita, Daisuke, Nagao, Toshitaka, Takahashi, Hideaki, Saotome, Takashi, Okazaki, Masashi, Yamazaki, Keisuke, Okamoto, Isaku, Hirai, Hideaki, Saigusa, Natsuki, Fushimi, Chihiro, Masubuchi, Tatsuo, Miura, Kouki, Okazaki, Shin-ichi, Matsui, Hirooki, Okada, Takuro, Iwaki, Sho, Matsuki, Takashi, Hanyu, Kenji, Tsukahara, Kiyoaki, Oridate, Nobuhiko, and Tada, Yuichiro

Published
2020
Full Text
View/download PDF

3. Initial Safety Analysis of CapeOx for Elderly Patients With Advanced Gastric Cancer Patients: A Phase II Trial

Author

CHIN, KEISHO, primary, TAKAHARI, DAISUKE, additional, KAWABATA, RYOHEI, additional, HOSAKA, HISASHI, additional, SAITOU, SO, additional, SHIRAISHI, TAKESHI, additional, YABUSAKI, HIROSHI, additional, GOTO, MASAHIRO, additional, NAKAMURA, MASATO, additional, IMAMURA, HIROSHI, additional, SHINDO, YOSHIAKI, additional, NAGASHIMA, FUMIO, additional, ICHIKAWA, WATARU, additional, SAOTOME, TAKASHI, additional, YAMAMOTO, WATARU, additional, ISHIZUKA, NAOKI, additional, and YAMAGUCHI, KENSEI, additional

Published
2022
Full Text
View/download PDF

4. sj-docx-2-tam-10.1177_17588359221119538 – Supplemental material for Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma

Author

Kawakita, Daisuke, Nagao, Toshitaka, Takahashi, Hideaki, Kano, Satoshi, Honma, Yoshitaka, Hirai, Hideaki, Saigusa, Natsuki, Akazawa, Kohei, Tani, Kaori, Ojiri, Hiroya, Tsukahara, Kiyoaki, Ozawa, Hiroyuki, Okami, Kenji, Kondo, Takahito, Togashi, Takafumi, Fushimi, Chihiro, Shimura, Tomotaka, Shimizu, Akira, Okamoto, Isaku, Okada, Takuro, Imanishi, Yorihisa, Watanabe, Yoshihiro, Otsuka, Kuninori, Sakai, Akihiro, Ebisumoto, Koji, Sato, Yuichiro, Yamazaki, Keisuke, Ueki, Yushi, Hanazawa, Toyoyuki, Saito, Yuki, Ando, Mizuo, Matsuki, Takashi, Nakaguro, Masato, Sato, Yukiko, Urano, Makoto, Utsumi, Yoshitaka, Kohsaka, Shinji, Saotome, Takashi, and Tada, Yuichiro

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-2-tam-10.1177_17588359221119538 for Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma by Daisuke Kawakita, Toshitaka Nagao, Hideaki Takahashi, Satoshi Kano, Yoshitaka Honma, Hideaki Hirai, Natsuki Saigusa, Kohei Akazawa, Kaori Tani, Hiroya Ojiri, Kiyoaki Tsukahara, Hiroyuki Ozawa, Kenji Okami, Takahito Kondo, Takafumi Togashi, Chihiro Fushimi, Tomotaka Shimura, Akira Shimizu, Isaku Okamoto, Takuro Okada, Yorihisa Imanishi, Yoshihiro Watanabe, Kuninori Otsuka, Akihiro Sakai, Koji Ebisumoto, Yuichiro Sato, Keisuke Yamazaki, Yushi Ueki, Toyoyuki Hanazawa, Yuki Saito, Mizuo Ando, Takashi Matsuki, Masato Nakaguro, Yukiko Sato, Makoto Urano, Yoshitaka Utsumi, Shinji Kohsaka, Takashi Saotome and Yuichiro Tada in Therapeutic Advances in Medical Oncology

Published
2022
Full Text
View/download PDF

5. sj-docx-4-tam-10.1177_17588359221119538 – Supplemental material for Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma

Author

Kawakita, Daisuke, Nagao, Toshitaka, Takahashi, Hideaki, Kano, Satoshi, Honma, Yoshitaka, Hirai, Hideaki, Saigusa, Natsuki, Akazawa, Kohei, Tani, Kaori, Ojiri, Hiroya, Tsukahara, Kiyoaki, Ozawa, Hiroyuki, Okami, Kenji, Kondo, Takahito, Togashi, Takafumi, Fushimi, Chihiro, Shimura, Tomotaka, Shimizu, Akira, Okamoto, Isaku, Okada, Takuro, Imanishi, Yorihisa, Watanabe, Yoshihiro, Otsuka, Kuninori, Sakai, Akihiro, Ebisumoto, Koji, Sato, Yuichiro, Yamazaki, Keisuke, Ueki, Yushi, Hanazawa, Toyoyuki, Saito, Yuki, Ando, Mizuo, Matsuki, Takashi, Nakaguro, Masato, Sato, Yukiko, Urano, Makoto, Utsumi, Yoshitaka, Kohsaka, Shinji, Saotome, Takashi, and Tada, Yuichiro

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-4-tam-10.1177_17588359221119538 for Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma by Daisuke Kawakita, Toshitaka Nagao, Hideaki Takahashi, Satoshi Kano, Yoshitaka Honma, Hideaki Hirai, Natsuki Saigusa, Kohei Akazawa, Kaori Tani, Hiroya Ojiri, Kiyoaki Tsukahara, Hiroyuki Ozawa, Kenji Okami, Takahito Kondo, Takafumi Togashi, Chihiro Fushimi, Tomotaka Shimura, Akira Shimizu, Isaku Okamoto, Takuro Okada, Yorihisa Imanishi, Yoshihiro Watanabe, Kuninori Otsuka, Akihiro Sakai, Koji Ebisumoto, Yuichiro Sato, Keisuke Yamazaki, Yushi Ueki, Toyoyuki Hanazawa, Yuki Saito, Mizuo Ando, Takashi Matsuki, Masato Nakaguro, Yukiko Sato, Makoto Urano, Yoshitaka Utsumi, Shinji Kohsaka, Takashi Saotome and Yuichiro Tada in Therapeutic Advances in Medical Oncology

Published
2022
Full Text
View/download PDF

6. sj-docx-3-tam-10.1177_17588359221119538 – Supplemental material for Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma

Author

Kawakita, Daisuke, Nagao, Toshitaka, Takahashi, Hideaki, Kano, Satoshi, Honma, Yoshitaka, Hirai, Hideaki, Saigusa, Natsuki, Akazawa, Kohei, Tani, Kaori, Ojiri, Hiroya, Tsukahara, Kiyoaki, Ozawa, Hiroyuki, Okami, Kenji, Kondo, Takahito, Togashi, Takafumi, Fushimi, Chihiro, Shimura, Tomotaka, Shimizu, Akira, Okamoto, Isaku, Okada, Takuro, Imanishi, Yorihisa, Watanabe, Yoshihiro, Otsuka, Kuninori, Sakai, Akihiro, Ebisumoto, Koji, Sato, Yuichiro, Yamazaki, Keisuke, Ueki, Yushi, Hanazawa, Toyoyuki, Saito, Yuki, Ando, Mizuo, Matsuki, Takashi, Nakaguro, Masato, Sato, Yukiko, Urano, Makoto, Utsumi, Yoshitaka, Kohsaka, Shinji, Saotome, Takashi, and Tada, Yuichiro

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-3-tam-10.1177_17588359221119538 for Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma by Daisuke Kawakita, Toshitaka Nagao, Hideaki Takahashi, Satoshi Kano, Yoshitaka Honma, Hideaki Hirai, Natsuki Saigusa, Kohei Akazawa, Kaori Tani, Hiroya Ojiri, Kiyoaki Tsukahara, Hiroyuki Ozawa, Kenji Okami, Takahito Kondo, Takafumi Togashi, Chihiro Fushimi, Tomotaka Shimura, Akira Shimizu, Isaku Okamoto, Takuro Okada, Yorihisa Imanishi, Yoshihiro Watanabe, Kuninori Otsuka, Akihiro Sakai, Koji Ebisumoto, Yuichiro Sato, Keisuke Yamazaki, Yushi Ueki, Toyoyuki Hanazawa, Yuki Saito, Mizuo Ando, Takashi Matsuki, Masato Nakaguro, Yukiko Sato, Makoto Urano, Yoshitaka Utsumi, Shinji Kohsaka, Takashi Saotome and Yuichiro Tada in Therapeutic Advances in Medical Oncology

Published
2022
Full Text
View/download PDF

7. sj-docx-1-tam-10.1177_17588359221119538 – Supplemental material for Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma

Author

Kawakita, Daisuke, Nagao, Toshitaka, Takahashi, Hideaki, Kano, Satoshi, Honma, Yoshitaka, Hirai, Hideaki, Saigusa, Natsuki, Akazawa, Kohei, Tani, Kaori, Ojiri, Hiroya, Tsukahara, Kiyoaki, Ozawa, Hiroyuki, Okami, Kenji, Kondo, Takahito, Togashi, Takafumi, Fushimi, Chihiro, Shimura, Tomotaka, Shimizu, Akira, Okamoto, Isaku, Okada, Takuro, Imanishi, Yorihisa, Watanabe, Yoshihiro, Otsuka, Kuninori, Sakai, Akihiro, Ebisumoto, Koji, Sato, Yuichiro, Yamazaki, Keisuke, Ueki, Yushi, Hanazawa, Toyoyuki, Saito, Yuki, Ando, Mizuo, Matsuki, Takashi, Nakaguro, Masato, Sato, Yukiko, Urano, Makoto, Utsumi, Yoshitaka, Kohsaka, Shinji, Saotome, Takashi, and Tada, Yuichiro

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tam-10.1177_17588359221119538 for Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma by Daisuke Kawakita, Toshitaka Nagao, Hideaki Takahashi, Satoshi Kano, Yoshitaka Honma, Hideaki Hirai, Natsuki Saigusa, Kohei Akazawa, Kaori Tani, Hiroya Ojiri, Kiyoaki Tsukahara, Hiroyuki Ozawa, Kenji Okami, Takahito Kondo, Takafumi Togashi, Chihiro Fushimi, Tomotaka Shimura, Akira Shimizu, Isaku Okamoto, Takuro Okada, Yorihisa Imanishi, Yoshihiro Watanabe, Kuninori Otsuka, Akihiro Sakai, Koji Ebisumoto, Yuichiro Sato, Keisuke Yamazaki, Yushi Ueki, Toyoyuki Hanazawa, Yuki Saito, Mizuo Ando, Takashi Matsuki, Masato Nakaguro, Yukiko Sato, Makoto Urano, Yoshitaka Utsumi, Shinji Kohsaka, Takashi Saotome and Yuichiro Tada in Therapeutic Advances in Medical Oncology

Published
2022
Full Text
View/download PDF

9. Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma

Author

Kawakita, Daisuke, primary, Nagao, Toshitaka, additional, Takahashi, Hideaki, additional, Kano, Satoshi, additional, Honma, Yoshitaka, additional, Hirai, Hideaki, additional, Saigusa, Natsuki, additional, Akazawa, Kohei, additional, Tani, Kaori, additional, Ojiri, Hiroya, additional, Tsukahara, Kiyoaki, additional, Ozawa, Hiroyuki, additional, Okami, Kenji, additional, Kondo, Takahito, additional, Togashi, Takafumi, additional, Fushimi, Chihiro, additional, Shimura, Tomotaka, additional, Shimizu, Akira, additional, Okamoto, Isaku, additional, Okada, Takuro, additional, Imanishi, Yorihisa, additional, Watanabe, Yoshihiro, additional, Otsuka, Kuninori, additional, Sakai, Akihiro, additional, Ebisumoto, Koji, additional, Sato, Yuichiro, additional, Yamazaki, Keisuke, additional, Ueki, Yushi, additional, Hanazawa, Toyoyuki, additional, Saito, Yuki, additional, Ando, Mizuo, additional, Matsuki, Takashi, additional, Nakaguro, Masato, additional, Sato, Yukiko, additional, Urano, Makoto, additional, Utsumi, Yoshitaka, additional, Kohsaka, Shinji, additional, Saotome, Takashi, additional, and Tada, Yuichiro, additional

Published
2022
Full Text
View/download PDF

10. Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade

Author

Lassche, Gerben, primary, Tada, Yuichiro, additional, van Herpen, Carla M. L., additional, Jonker, Marianne A., additional, Nagao, Toshitaka, additional, Saotome, Takashi, additional, Hirai, Hideaki, additional, Saigusa, Natsuki, additional, Takahashi, Hideaki, additional, Ojiri, Hiroya, additional, van Engen-Van Grunsven, Adriana C. H., additional, Schalken, Jack A., additional, Fushimi, Chihiro, additional, and Verhaegh, Gerald W., additional

Published
2021
Full Text
View/download PDF

14. Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Salivary Duct Carcinoma

Author

Takahashi, Hideaki, primary, Tada, Yuichiro, additional, Saotome, Takashi, additional, Akazawa, Kohei, additional, Ojiri, Hiroya, additional, Fushimi, Chihiro, additional, Masubuchi, Tatsuo, additional, Matsuki, Takashi, additional, Tani, Kaori, additional, Osamura, Robert Y., additional, Hirai, Hideaki, additional, Yamada, Shuhei, additional, Kawakita, Daisuke, additional, Miura, Kouki, additional, Kamata, Shin-etsu, additional, and Nagao, Toshitaka, additional

Published
2019
Full Text
View/download PDF

18. Phase I/II study of docetaxel, cisplatin and S-1 in locally advanced, recurrent and metastatic head and neck squamous cell carcinoma

Author

TADA, YUICHIRO, primary, MARUYA, SHIN-ICHIRO, additional, SAOTOME, TAKASHI, additional, MIURA, KOUKI, additional, MASUBUCHI, TATSUO, additional, FUSHIMI, CHIHIRO, additional, OKAMOTO, ISAKU, additional, TAKEISHI, ETSURO, additional, YAMADA, SHUHEI, additional, ASAI, HIROAKI, additional, and KAMATA, SHIN-ETSU, additional

Published
2012
Full Text
View/download PDF

20. Dose-Dense Weekly Rituximab and Standard CHOP Therapy in 123 Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma; Ganken Ariake Lymphoma Study Group Analysis.

Author

Yokoyama, Masahiro, primary, Terui, Yasuhito, additional, Takeuchi, Kengo, additional, Asai, Hiroaki, additional, Kodaira, Makoto, additional, Ueda, Kyoko, additional, Yamada, Shuhei, additional, Mishima, Yuko, additional, Sakajiri, Sakura, additional, Saotome, Takashi, additional, Takahashi, Shunji, additional, and Hatake, Kiyohiko, additional

Published
2009
Full Text
View/download PDF

21. The Efficacy of R-ICE Therapy as a Salvage Treatment for Relapse and Refractory Diffuse Large B-Cell Lymphoma.

Author

Kodaira, Makoto, primary, Yokoyama, Masahiro, additional, Asai, Hiroaki, additional, Yamada, Shuhei, additional, Ueda, Kyoko, additional, Myojo, Tomohiro, additional, Nishimura, Tomoko, additional, Mishima, Yuko, additional, Sakajiri, Sakura, additional, Takeuchi, Kengo, additional, Saotome, Takashi, additional, Terui, Yasuhito, additional, Takahashi, Shunji, additional, and Hatake, Kiyohiko, additional

Published
2007
Full Text
View/download PDF

22. Addition of Rituximab to CHOP Chemotherapy Does Not Improve Clinical Outcome in Patients with Localized Gastric Diffuse Large B-Cell Lymphoma: A Retrospective Study by Ganken Adult Lymphoma Study Group (Single Institute Analysis).

Author

Yokoyama, Masahiro, primary, Ennishi, Daisuke, additional, Asai, Hiroaki, additional, Ueda, Kyoko, additional, Kodaira, Makoto, additional, Yamada, Shuhei, additional, Myojo, Tomohiro, additional, Mishima, Yuko, additional, Sakajiri, Sakura, additional, Takeuchi, Kengo, additional, Saotome, Takashi, additional, Terui, Yasuhito, additional, Takahashi, Shunji, additional, Ito, Yoshinori, additional, and Hatake, Kiyohiko, additional

Published
2007
Full Text
View/download PDF

23. Addition of Rituximab to CHOP Regimen Improves Clinical Outcome in Non-Germinal Center Type Diffuse Large B-Cell Lymphoma.

Author

Yokoyama, Masahiro, primary, Ennishi, Daisuke, additional, Ueda, Kyoko, additional, Kodaira, Makoto, additional, Yamada, Shuhei, additional, Myojo, Tomohiro, additional, Sakajiri, Sakura, additional, Mishima, Yuko, additional, Takeuchi, Kengo, additional, Saotome, Takashi, additional, Terui, Yasuhito, additional, Takahashi, Shunji, additional, Ito, Yoshinori, additional, and Hatake, Kiyohiko, additional

Published
2006
Full Text
View/download PDF

26. Reduced tumorigenicity of human gastric carcinoma cells engineered to produce IL-2 in SCID mice reconstituted with peripheral blood cells from cancer patients

Author

Tagawa, Masatoshi, primary, Goto, Shigemasa, additional, Takenaga, Keizo, additional, Takeshita, Akihiro, additional, Saotome, Takashi, additional, Takenouchi, Toshinao, additional, Tsurumachi, Tetuya, additional, Gunji, Yoshio, additional, Matsubara, Hisahiro, additional, and Sakiyama, Shigeru, additional

Published
1998
Full Text
View/download PDF

27. Chemotherapy with Irinotecan (CPT-11), a Topoisomerase-I Inhibitor, for Refractory and Relapsed Non-Hodgekin's Lymphoma.

Author

Takagi, Toshiyuki and Saotome, Takashi

Subjects
*DNA topoisomerase I, *LYMPHOMAS, *DRUG therapy, *CHEMICAL inhibitors
Abstract

Investigates the effectiveness of irinotecan (CPT-11) chemotherapy, a topoisomerase-I inhibitor for refractory and relapsed non-Hodgkin's lymphoma. Characteristics of CPT-11; Potentiality of CPT-11 combined with topoisomerase-II inhibitor; Antitumor effects of CPT-11 combined with other anticancer drugs.

Published
2001
Full Text
View/download PDF

28. [A Case of a Metastatic Liver Tumor from a Thymic Carcinoma Detected During a Cesarean Section].

Author

Morinaka T, Takeuchi D, Noro A, Saotome T, Yoshimura K, Kaneko T, Miura S, Kamiya J, Ashizawa Y, Akikusa B, and Ogata A

Subjects
Adult, Cesarean Section, Female, Hepatectomy, Humans, Liver Neoplasms surgery, Lung Neoplasms secondary, Pregnancy, Thymoma pathology, Liver Neoplasms secondary, Thymoma diagnosis
Abstract

A 40-year-old pregnant woman who had previously been diagnosed with uterine myoma underwent cesarean section. During the operation, a tumor thought to be uterine myoma was found to be an extrauterine tumor arising from the upper abdomen. After the delivery of the fetus, a staging CT scan was performed, which revealed a huge, 18 cm, hepatic tumor in the left lateral segment, a mediastinal tumor with calcification, and multiple lung nodules. She underwent a left hepatic lobectomy and a wedge resection 8 days after the delivery. The initial pathological diagnosis was moderately differentiated neuroendocrine tumor (NET). However, as a primary hepatic NET is extremely rare, further immunohistochemical staining was performed. The tumor was positive for p63, CD5, c-kit, and bcl-2, indicating a diagnosis of thymic carcinoma with liver and lung metastases.

Published
2015

29. [Efficacy of CHOP+/-Rituximab-like therapy plus radiation therapy for patients with diffuse large B-cell lymphoma stage I].

Author

Ueda K, Yokoyama M, Asai H, Koudaira M, Yamada S, Katsube A, Mishima Y, Sakajiri S, Takeuchi K, Saotome T, Terui Y, Takahashi S, and Hatake K

Subjects
Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal immunology, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Combined Modality Therapy, Cyclophosphamide administration & dosage, Cyclophosphamide therapeutic use, Disease Progression, Doxorubicin administration & dosage, Doxorubicin therapeutic use, Female, Follow-Up Studies, Humans, Lymphoma, Large B-Cell, Diffuse immunology, Lymphoma, Large B-Cell, Diffuse pathology, Male, Middle Aged, Neoplasm Staging, Prednisone administration & dosage, Prednisone therapeutic use, Rituximab, Survival Rate, Vincristine administration & dosage, Vincristine therapeutic use, Antibodies, Monoclonal therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse radiotherapy
Abstract

Clinically, R-CHOP-like therapy plus radiation therapy is commonly performed for patients with limited stage diffuse large B-cell lymphoma. However, the efficacy and the safety of the management have not been evaluated properly. In particular, we have few definitive reports about patients with stage I DLBCL. This time we evaluated the effect of CHOP+/-R-like therapy plus radiation therapy, by analyzing 28 patients with stage I DLBCL, retrospectively. 15 patients were treated with the RCHOP-like therapy, and 13 received CHOP-like therapy combined with radiation therapy. A complete response was observed in all of the patients. With a median follow-up time of 14 months, 1-year progression-free survival (PFS) was 100%, and the 1-year overall survival (OS) was 100% for the patients receiving the R-CHOP-like therapy. With a median follow-up time of 68 months, 5-year PFS was 84. 6%, and 5-year OS was 100% for patients receiving the CHOP-like therapy. Since the followup time was not enough and the patient numbers were too few, the benefit of the addition of Rituximab to the CHOP therapy could not be clarified. We need to assess the safety and the efficacy of the combined modality therapy for patients with limited-stage DLBCL by a larger prospective study.

Published
2010

30. [A case of mediastinal cancer of unknown primary with elevation of serum concentrations of interleukin-6].

Author

Kobayashi K, Myojo T, Saotome T, Takahashi S, and Hatake K

Subjects
Aged, Biopsy, Humans, Male, Mediastinal Neoplasms pathology, Mediastinal Neoplasms radiotherapy, Neoplasms, Unknown Primary diagnostic imaging, Neoplasms, Unknown Primary radiotherapy, Tomography, X-Ray Computed, Interleukin-6 blood, Mediastinal Neoplasms blood, Mediastinal Neoplasms secondary, Neoplasms, Unknown Primary blood, Neoplasms, Unknown Primary pathology
Abstract

Interleukin-6(IL-6)is an inflammatory cytokine. It's produced by monocyte, lymphocyte, vascular endothelial cell, and fibroblast. Elevation of serum concentrations of IL-6 is reported a lot of kind of diseases, such as cancer, infection, inflammatory diseases. But it is production mechanism was still unknown. A 67-year-old man was referred to our hospital because of treatment against the large mediastinal cancer of unknown primary. He had complication with superior vena cave syndrome. After he was exposed to irradiation, the tumor size was reduced, his symptoms were improved and the serum IL-6 level was decreased.

Published
2008

31. [A pilot study of TS-1+CDDP therapy for highly advanced stage IV gastric cancer].

Author

Sakai Y, Saotome T, Fujimori M, Shimizu S, Inkyo T, Yugeta H, Ohbu M, Koma Y, Sato T, Nagashima F, Hayasaka A, Fukuyama Y, Tsuchiya S, Tsuyuguchi T, and Saisho H

Subjects
Administration, Oral, Adult, Aged, Carcinoma, Signet Ring Cell surgery, Cisplatin administration & dosage, Combined Modality Therapy, Drug Administration Schedule, Drug Combinations, Female, Humans, Male, Middle Aged, Oxonic Acid administration & dosage, Paclitaxel administration & dosage, Pilot Projects, Pyridines administration & dosage, Quality of Life, Stomach Neoplasms surgery, Tegafur administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Signet Ring Cell drug therapy, Stomach Neoplasms drug therapy
Abstract

We performed a pilot study of combination chemotherapy with TS-1 and cisplatin for highly advanced gastric cancer. From June 2002, 12 patients with multiple liver metastases, carcinomatous lymphangitis or peritoneal dissemination, were enrolled in the study. TS-1 was administered at a daily dose on day 1-21 and an intermediate-dose of cisplatin (60 mg/m2) was administered on day 8. The combination was repeated in a 5-week cycle. The median administered cycles were three (one to eight). An objective response was obtained in 9 cases (75.0%) of primary sites and 6 cases of metastatic sites. No severe hematological toxicity occurred, and grade 3 stomatitis (in one case) and vomiting (in two cases) occurred as non-hematological toxicities. The improvement of clinical symptoms such as appetite loss and abdominal discomfort was obtained in 9 of 10 cases. The median survival time is 244 days. The TS-1/CDDP regimen had almost no survival benefits, but may induce relief of symptoms due to cancer and better quality of life.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results